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Abstract
Introduction—The incident-user design is the preferred study design in comparative 
effectiveness (CER) research. Usually 180–365 days of exposure free time is adequate to remove 
biases associated with inclusion of prevalent users. In HIV research, the use of antiretrovirals at 
any time in the past may influence future treatment choices and CER results; thus identifying 
naïve as opposed to incident users is of importance. We examined misclassification of 
antiretroviral naïve status based on Medicaid administrative data through linkage to the UNC 
CFAR HIV Clinical Cohort (UCHCC).
Methods—We identified Medicaid patients with incident exposure to common first-line ARV 
regimens between 2002 and 2008 that were also patients enrolled in the UCHCC. We calculated 
the proportion of antiretroviral naïve patients based on the UCHCC, among patients identified as 
having incident exposure in Medicaid and examined factors associated with being antiretroviral 
naive in both data sources using logistic regression to generate prevalence odds ratios and 
associated 95% confidence intervals.
Results—Of the 3,500 Medicaid patients with incident antiretroviral exposure, 1,344 were also 
enrolled in the UCHCC. In this sample, 34% were antiretroviral naïve at the time of first exposure 
in the Medicaid data based on the UCHCC. In multivariable models, higher CD4 cell counts and 
log HIV RNA values were associated with being antiretroviral naïve in both data sources.
Conclusions—Administrative data are an important source of information related to HIV 
treatment. As the construction of a durable and long-lasting HIV treatment plan involves 
knowledge of current and past ART, augmentation of this data with comprehensive clinical cohort 
information is necessary.
Introduction
In comparative effectiveness research (CER), the new- or incident -user, design is preferred 
over prevalent-user study designs. [1, 2] By including only patients initiating a medication 
or intervention at a given point of time, it is possible to avoid potential biases related to 
adjustment of covariates that lie on the causal pathway as well as depletion of patients 
susceptible to an outcome early in treatment.[1–3] [1–3] When conducting CER using 
administrative databases, incident-users are identifiable because of documentation of 
insurance/healthcare eligibility as well as the availability of medical claims data for those 
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who receive treatment. Currently there is no consensus for the amount of exposure free time 
(e.g. wash-out, run-in) that is required prior to the identification of incident use and it is 
usually determined arbitrarily and often constrained by sample size and availability of data. 
[4] Strict definitions result in increased internal validity but at the cost of statistical power.
[4]
Most CER studies use 180–365 days of medication exposure free time directly preceding the 
initiation of treatment to remove most biases associated with the inclusion of prevalent 
users. However, with conditions like HIV, the use of antiretrovirals at any time, and not just 
the previous six months to a year, must also be a consideration. Incident-users of 
antiretrovirals, as defined using administrative data, may not be antiretroviral naïve. The 
construction of a durable and long-lasting HIV treatment regimen is complicated and 
involves attention to past and current antiretroviral regimens. Patients receiving 
antiretroviral treatment in the past may have discontinued treatment due to side effects or 
potentially due to the development of resistant virus. Therefore, through the linkage to a 
comprehensive HIV clinical cohort we aimed to quantify and describe the truly naïve 
patients in an incident use population identified in Medicaid administrative claims.
Methods
Our sample included incident-users of common first line antiretroviral regimens identified in 
the North Carolina Medicaid administrative data between 2002 and 2008 that were also 
patients enrolled in the UNC CFAR HIV Clinical Cohort (UCHCC). The UCHCC, 
described elsewhere [5], is a clinical cohort initiated in the year 2000 that includes all HIV 
infected patients seen at the UNC Infectious Diseases clinic that are 18 years of age or older 
and have provided written informed consent. The Medicaid program is a joint state and 
federally funded program that provides healthcare benefits to individuals of low income. 
The data from each source were linked by social security number, first name and last name. 
In the UCHCC, detailed medication histories including start and stop dates as well as 
clinical and sociodemographic characteristics are manually abstracted from the electronic 
medical record. Antiretroviral medications were identified in the Medicaid administrative 
data through national drug codes. Incident-users of antiretroviral medications were defined 
as Medicaid beneficiaries who met the following: (1) had a claim for one of the FDA 
approved antiretrovirals (2) had at least 180 days of continuous Medicaid eligibility prior to 
the antiretroviral claim, and (3) had no claim for any of the FDA approved antiretrovirals in 
the Medicaid administrative data during this 180 days period. Patients were classified as 
naïve if they did not have documented antiretroviral use in the UCHCC before the first 
Medicaid claim.
Using the incident-user sample described above, we calculated the proportion of incident-
users defined using the Medicaid data source who were also naïve based on recorded 
UCHCC medication history. Among the incident-users who had documented prior 
antiretroviral exposure based on the UCHCC, we calculated the difference between the two 
dates. A medication start date identified in the UCHCC that was within 7 days of the start 
date identified in the claims was considered to be an equivalent start date in the UCHCC. 
Among the incident-users who had documented prior antiretroviral exposure based on the 
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UCHCC, we calculated the difference between the two dates. We also evaluated differences 
in socio-demographic (age, race, sex), HIV infection risk factors (men who have sex with 
men, injection drug use) and clinical factors (CD4 cell count and log HIV RNA) among 
patients identified as naïve to those who were not-naïve (experienced). Time-varying factors 
(i.e., age, CD4 cell count and HIV RNA) were evaluated at the time antiretrovirals were 
initiated as defined by Medicaid claims. To evaluate factors independently associated with 
incident and naïve status, we estimated adjusted prevalence odds (POR) ratios using logistic 
regression with a backwards elimination strategy. This study was approved by the 
University of North Carolina Institutional Review Board.
Results
Of the 3,500 incident-users identified using the Medicaid administrative data, 1,344 were 
also enrolled in the UCHCC cohort. In this overlapping sample, 34% of the Medicaid 
incident users were naïve based on medical record abstraction of antiretroviral use 
documented in the UCHCC. The average time between antiretroviral initiation in the cohort 
and documented incident use in the Medicaid claims was 6.3 years (Range: 9 days-19.5 
years). Two and a half percent of patients initiated antiretrovirals within the 6 months prior 
to documentation of incident use in the Medicaid claims (e.g. during the run-in period). 
Fifty-four percent of patients initiated antiretrovirals more than five years prior to the first 
documented Medicaid claim.
Unadjusted results demonstrate that patients identified as incident-users in the Medicaid data 
and also naïve in the UCHCC were younger [Median: 42 (IQR: 25, 48) vs 43 years (IQR: 
38, 50)], less likely to use injection drugs (19% vs. 23%), and had similar CD4 cell count 
and HIV RNA lab values. In general the patient characteristics for the Medicaid sample 
were similar to the UCHCC with exception of HIV RNA; the overall UCHCC population 
had higher HIV RNA at entry into the cohort. (Table 1) Age, CD4 cell count and HIV RNA 
were all independently associated with naivety in adjusted logistic regression models. 
Higher CD4 cell counts and HIV RNA were associated with naivety in the UCHCC (POR: 
1.31/200 μ increase) [95% Confidence Interval (CI): 1.20, 1.43] and POR: 1.76/1 log 
increase (95% CI: 1.54, 2.01)]. Older patients were less likely to be naïve [POR: 0.14/10 
year increase in age (95% CI: 0.04, 0.48)]. (Table 2)
Discussion
By linking comprehensive clinical cohort data to administrative claims, we found that a 
large proportion of Medicaid patients that were identified as incident-users had 
documentation of past antiretroviral use based on comprehensive medical chart reviews 
documented in the UCHCC. As would be expected, age, HIV RNA and CD4 count were all 
predictors of naivety among the Medicaid incident use sample. Our results are in 
concordance with another recent study using Veteran’s Administration data that also found 
that HIV RNA was associated with naivety at the time of enrollment in a large clinical 
cohort.[6]
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There are several explanations for our observed results. First, current and past medication 
history is recorded in the UCHCC based on the medical record regardless of payer. 
Administrative claims only capture medications that the patient received and were paid for 
by insurance. It is possible that patients may have received free samples prior to initiating 
treatment, a likely scenario for patients that had documentation of first antiretroviral use in 
the UCHCC during the 6 month run-in period prior to incident use in the Medicaid data.
Switching of health insurance coverage in the HIV-infected population has been 
documented.[7,8] Patients that initiated treatment many years prior to documentation of 
incident use may have received their medications through a different insurance source 
earlier in their course of therapy and qualify and subsequently switch to Medicaid years after 
diagnosis. Another likely explanation is that patients fall out of care and reinitiate treatment 
at a later date at which point they qualify for Medicaid.[9] It has been shown that patients 
qualifying for Medicaid are more likely to be on antiretroviral medications and/or have an 
AIDS diagnosis, suggesting that patients become covered by Medicaid later in disease 
progression.[10]
A few options are available to increase the proportion of naïve patients included in the 
Medicaid incident-user sample. Restricting the Medicaid claims defined incident use 
population to common first line therapies would remove some of the patients who were lost 
and reentered care. Further, by increasing the wash-out period to 365 days, the proportion of 
incident-users that are also naïve would increase to greater than 50%.
Clinical cohorts provide a very comprehensive picture of HIV patients in clinical care, 
however, sample size often limits the ability to conduct CER of specific antiretroviral 
therapies. Administrative data provides increased power to conduct these studies but at the 
expense of potential exposure misclassification as well as absence of important clinical 
variables. The linkage of these two data sources provides valuable insight for future CER 
using administrative databases.
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• In comparative effectiveness research using administrative claims data, incident 
users of antiretroviral medications may not be naïve to antiretroviral 
medications
• Restricting inclusion criteria to patients initiating common first-line regimens or 
increasing the wash-out period would increase the number of incident users 
included in the study that are truly naïve to HIV treatment.
• Augmentation of administrative data with comprehensive clinical cohort 
information is a critical resource when conducting comparative effectiveness 
research of antiretroviral medications.
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Table 1
Clinical and socio-demographic characteristics of the UNC CFAR HIV Clinical Cohort (UCHCC) as well as 











 Female 204 (45) 347 (39) 1280 (29)
Age at antiretroviral start in Medicaid, Median (IQR) 42 (25, 48) 43 (38, 50) 37 (30, 44)*
Race
 White 90 (20) 192 (22) 1355 (31)
 Black 326 (72) 637 (72) 2612 (60)
 Other Race 38 (8) 61 (7) 389 (9)
Men who have sex with Men (MSM)
 Yes 107 (24) 226 (25.3) 1605 (39)
Intravenous Drug User (IDU)
 Yes 87 (19) 207 (23) 573 (14)
CD4 count (cells/μL) most proximal to Medicaid antiretroviral start (median, IQR) 325 (112, 583) 307 (137, 508) 300 (102, 500)*
Log10 HIV RNA (copies/mL) most proximal to Medicaid antiretroviral start 
(median, IQR)
2.8 (1.8, 4.2) 2.8 (1.7, 4.5) 4.4 (3.3, 5.1)*
*
Most proximal to entry into UCHCC
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Table 2
Predictors of naïve status in the UNC CFAR HIV Clinical Cohort Study (UCHCC) among patients identified 
as incident-users through Medicaid claims
Full Model Final Model
POR* 95% CI** POR* 95% CI**
Age per 10 year increase 0.14 0.04, 0.54 0.14 0.04, 0.48
Sex (Female) 1.16 0.87, 1.54 -- --
Race (Black vs. White and other race) 1.00 0.77, 1.32 -- --
IV Drug Use (yes) 0.93 0.68, 1.27 -- --
Men who have sex with men 0.96 0.69, 1.35 -- --
HIV RNA (log copies/mL)/1 log increase 1.64 1.48, 1.82 1.65 1.49, 1.63
CD4 Cell Count (cells/uL) per 200 cell increase 1.30 1.19, 1.42 1.31 1.20, 1.43
*
POR: Prevalence Odds Ratio
**
CI: Confidence Interval
Pharmacoepidemiol Drug Saf. Author manuscript; available in PMC 2015 May 10.
